, Volume 75, Issue 14, pp 1669–1678 | Cite as

Eliglustat: A Review in Gaucher Disease Type 1

  • Lesley J. Scott
Adis Drug Evaluation


Oral eliglustat (Cerdelga®) is approved in several countries for the long-term treatment of adults with Gaucher disease type 1 (GD1) who are cytochrome P450 (CYP) 2D6 extensive metabolizers (EMs), intermediate metabolizer (IMs) or poor metabolizers (PMs) [these three CYP categories encompass >90 % of individuals]. Eliglustat is a potent, selective inhibitor of glucosylceramide synthase, the rate-limiting enzyme in the synthesis of certain glycosphingolipids, and thus, reduces the rate of biosynthesis of glycosphingolipids to counteract the catabolic defect (i.e. substrate reduction therapy). In the 9-month phase 3 ENGAGE trial, eliglustat significantly improved haematological endpoints and reduced organomegaly compared with placebo in treatment-naive adults with GD1, with the bone marrow burden score (a marker of Gaucher cell infiltration) and GD1 biomarkers also improving from baseline in eliglustat recipients. After 12 months in the phase 3 ENCORE trial, oral eliglustat was noninferior to intravenous imiglucerase [an enzyme replacement therapy (ERT)] in maintaining disease stability in adults who had stable disease after receiving ERT for ≥3 years. During long-term treatment with eliglustat (≤4 years) in the extension period of each of these pivotal trials and a phase 2 trial, patients experienced sustained improvements in visceral, haematological and skeletal endpoints, with no new safety concerns identified. Further clinical experience will help to more definitively establish the position of eliglustat treatment in adults with GD1. In the meantime, with its convenient oral regimen, eliglustat is an emerging alternative therapy to ERT for the long-term treatment of adults with GD1 who are CYP2D6 EMs, IMs or PMs.


Enzyme Replacement Therapy Liver Volume Fatigue Severity Scale Miglustat Spleen Volume 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflict of interest

Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Martins AM, Valadares ER, Porta G, et al. Recomendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr. 2009;155(4 Suppl 2):S10–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Wang RY, Bodamer OA, Watson MS, et al. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med. 2011;13(5):457–84.CrossRefPubMedGoogle Scholar
  3. 3.
    Genzyme Corporation. Cerezyme® imiglucerase for injection: US prescribing information. 2011. Accessed 5 Aug 2015.
  4. 4.
    Grabowski GA. Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program. 2012;2012:13–5.PubMedGoogle Scholar
  5. 5.
    European Medicines Agency. Cerdelga: summary of product characteristics. 2015. Accessed 8 June 2015.
  6. 6.
    Hicks JK, Swen JJ, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93(5):402–8.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    McEachern KA, Fung J, Komarnitsky S, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab. 2007;91(3):259–67.CrossRefPubMedGoogle Scholar
  8. 8.
    Marshall J, McEachern KA, Chuang WL, et al. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis. 2010;33(3):281–9.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Genzyme Ireland Ltd. Cerdelga® (eliglustat) capsules, for oral use: US prescribing information. 2014. Accessed 8 June 2015.
  10. 10.
    Peterschmitt MJ, Burke A, Blankstein L, et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol. 2011;51(5):695–705.CrossRefPubMedGoogle Scholar
  11. 11.
    Mistry PK, Lukina E, Ben Turkia H, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015;313(7):695–706.CrossRefPubMedGoogle Scholar
  12. 12.
    Cox TM, Drelichman G, Cravo R, et al. Eliglustat compared with imiglucerase in patients with Gaucher’s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015;385(9985):2355–62.CrossRefPubMedGoogle Scholar
  13. 13.
    Lukina E, Watman N, Arreguin EA, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116(6):893–9.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Lukina E, Watman N, Dragosky M, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis. 2014;53(4):274–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Kamath RS, Lukina E, Watman N, et al. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol. 2014;43(10):1353–60.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 2010;116(20):4095–8.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Peterschmitt MJ, Taylor JS, Angell J, et al. Clinical response to eliglustat in treatment-naive patients with Gaucher disease type 1: post-hoc comparison to imiglucerase in a real-world setting [abstract]. Mol Genet Metab. 2015;114(2):S93.CrossRefGoogle Scholar
  18. 18.
    Giraldo P, Pleat R, Angell J, et al. Stability is maintained in adult patients with Gaucher disease type 1 (GD1) switched from velaglucerase alfa to eliglustat: a sub-analysis of the eliglustat, phase 3 ENCORE trial [abstract no. P-610]. J Inherit Metab Dis. 2015;38(Suppl 1):S296–7.Google Scholar
  19. 19.
    Mistry P, Amato DJ, Dasouki M, et al. ENGAGE - a phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with Gaucher disease type 1: results after 18 months [abstract]. Mol Genet Metab. 2015;114(2):S81–2.CrossRefGoogle Scholar
  20. 20.
    Cox TM, Drelichman GI, Cravo R, et al. ENCORE, a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results [abstract]. Mol Genet Metab. 2015;114(2):S33–4.CrossRefGoogle Scholar
  21. 21.
    Pastores GM, Weinreb NJ, Aerts JM, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(Suppl 5):4–14.CrossRefPubMedGoogle Scholar
  22. 22.
    Ross L, Peterschmitt J, Puga AC, et al. Eliglustat safety profile based on a pooled analysis of data from four trials in Gaucher disease type I [abstract]. Mol Genet Metab. 2014;111(2):S90.CrossRefGoogle Scholar
  23. 23.
    Lau H, Ibrahim J, Peterschmitt MJ, et al. Tremor and peripheral neuropathy are infrequent and non-serious events in Gaucher type 1 patients treated with eliglustat [abstract]. Mol Genet Metab. 2015;114(2):S69–70.Google Scholar
  24. 24.
    Hughes D, Cappellini MD, Berger M, et al. Recommendations for the management of haematological and onco-haematological aspects of Gaucher disease. Brit J Haematol. 2007;136:676–86.CrossRefGoogle Scholar
  25. 25.
    Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1; revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. 2004;41(Suppl 5):15–22.CrossRefPubMedGoogle Scholar
  26. 26.
    European Medicines Agency. Zavesca 100 mg hard capsules: summary of product characteristics. 2012. Accessed 26 June 2015.
  27. 27.
    Actelion Pharmaceuticals US Inc. Zavesca® (miglustat) capsules, for oral use: US prescribing information. 2014. Accessed 26 June 2015.
  28. 28.
    Shayman JA. Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future. 2010;35(8):613–20.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Shayman JA, Larsen SD. The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases. J Lipid Res. 2014;55(7):1215–25.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations